BNP/CALL/MODERNA/90/0.1/20.12.24 | Delayed Deutsche Boerse AG 12:50:29 2024-06-28 pm EDT | ||
| 3.4 EUR | -7.36% |
|
| Current month | -32.54% | ||
| 1 month | -51.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 3.4 | -7.36% |
| 24-06-27 | 3.67 | -3.42% |
| 24-06-26 | 3.8 | -23.08% |
| 24-06-25 | 4.94 | +0.20% |
| 24-06-24 | 4.93 | +4.67% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 12:50 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN7E4F |
| ISIN | DE000PN7E4F5 |
| Date issued | 2023-08-17 |
| Strike | 90 $ |
| Maturity | 2024-12-20 (175 Days) |
| Parity | 10 : 1 |
| Emission price | 2.75 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.74 € |
|---|---|
| Lowest since issue | 0.97 € |
| Spread | 0.01 € |
| Spread % | 0.29% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
121.2
USD
Average target price
145.9
USD
Spread / Average Target
+20.36%
- Stock Market
- Warrants
- Warrant
